Skip to main content
OpenTrials
Completed

NCT Number: NCT00996177

A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously

The purpose of this study is to evaluate the effectiveness and safety of a patient-controlled system to deliver fentanyl compared with a patient-controlled intravenous system to deliver morphine in the management of postoperative pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Vienna, Austria

Loading trial locations.

About this study

This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention) study to evaluate the clinical use, safety and ease of care of two patient-controlled analgesia (PCA) systems to deliver pain medication either through the skin or intravenously. The fentanyl hydrochloride PCA system, which delivers the medication through the skin, and morphine intravenous (IV)- PCA, which requires injection into a vein, are used for management of moderate to severe acute pain in postoperative patients who have undergone elective major abdominal or orthopedic surgery. These patients, who are expected to require postoperative pain relief with strong opioids for at least 24 hours, will control the delivery of medication for up to 3 days. Assessment of effectiveness include: patient's global assessment of pain control (poor, fair, good, excellent); Pain Intensity, measured on a visual numerical rating scale from 0 to 10, where 0 means no pain and 10 means the worst possible pain; Ease-of-Care questionnaires including Patient Ease-of-Care questionnaire, Nurse Ease-of-Care questionnaire, and Physical Therapist Ease-of-Care questionnaire; and, total number of doses delivered by patients in the fentanyl transdermal PCA or morphine IV PCA treatment groups. Safety evaluations include vital signs (pulse, blood pressure) and oxygen saturation, respiratory function, and the incidence of adverse events. The study hypothesis is that fentanyl transdermal PCA is not inferior to morphine IV PCA treatment in patient's global assessment of method of pain control during the first 24 hours after surgery. Transdermal PCA: 40 micrograms fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours (maximum of 80 doses, 3.2milligrams). Morphine IV PCA: morphine doses with a maximum of 20 milligrams per 2 hours for 24 hours (maximum 12 doses, 240 milligrams).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who meet the criteria of American Society of Anesthesiology (ASA) pre-operative physical status I, II, or III
  • Patients expected to have moderate or severe pain after a major abdominal or orthopedic procedure
  • Patients expected to remain hospitalized for at least 24 hours postoperatively

Exclusion criteria

  • Known allergy or hypersensitivity to fentanyl, morphine, or to skin adhesives
  • Known or suspected to be dependent on strong opioids or to have abused any drug substance or alcohol
  • Severe respiratory symptoms
  • Chronic pain disorder
  • Pregnant or nursing women, or those lacking adequate contraception

Treatment and study plan

IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem

Drug

40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day

IV Morphine Patient-Controlled Analgesia (IV PCA)

Drug

20mg/2hr (240 mg during 24 hours)

Primary outcomes

  1. Patient's global assessment of pain control (poor, fair, good, excellent) 24 hours after start of study treatment

    Time frame: 24 hours after randomization (24 hours after either the first transdermal iontorphoretic system was applied or 24 hours after the intravenous access for the morphine solution was applied).

Secondary outcomes

  1. Assessment of pain control by patient and doctor

    Time frame: At 24, 48, and 72 hours after randomization

  2. Pain Intensity, vital signs, and oxygen level in the blood

    Time frame: Hourly through 8 hours and then every 4 hours after randomization

  3. Incidence of adverse events

    Time frame: Throughout study

Sponsors and collaborators

Lead sponsor

Janssen-Cilag International NV

Industry

Collaborators

  • Alza Corporation, DE, USA

Registry information

Official study title

Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control

Acronym: EuroTrans

Important dates

Study start
2004
Primary completion
2005
Study completion
2005
First posted
Oct 16, 2009
Registry last updated
Jan 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.